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Summary
We previously demonstrated that the NC1[a3(IV)185–
191] CNYYSNS peptide inhibited in vivo tumor pro-
gression. The YSNS motif formed a b turn crucial for
biological activity. The aim of the present study was
to design a YSNSG cyclopeptide with a constrained
b turn on the YSNS residues more stable than
CNYYSNS. By nuclear magnetic resonance and molec-
ular modeling, we demonstrated that the YSNSG
cyclopeptide actually adopted the expected b-turn
conformation. It promoted melanoma cell adhesion
and prevented their adhesion to the native peptide. It
inhibited in vitro cell proliferation and migration
through Matrigel by downregulating proteolytic cas-
cades. Moreover, intraperitoneal administration of
the YSNSG cyclopeptide inhibited melanoma progres-
sion far more efficiently than the native peptide. The
increased solubility and stability at low pH of the
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CNRS UPR 2301, 91198 Gif-sur-Yvette, France.YSNSG cyclopeptide suggest this peptide as a potent
antitumor therapeutic agent.
Introduction
Tumor invasion and metastasis require proteolytic deg-
radation of extracellular matrix (ECM). This degradation
involves various proteolytic cascades, such as matrix
metalloproteinase (MMP) activation and the plasmi-
nogen activation system. MMPs belong to a zinc-depen-
dent proteinase family with more than 25 members,
secreted as inactive zymogens [1, 2]. Their activation,
a major step in tumor invasion, results from an imbal-
ance between levels of tissue inhibitors of metalloprotei-
nases (TIMPs) and MMP activators, such as urokinase,
plasmin, or membrane type MMPs (MT-MMPs). The
latter constitutes an MMP subfamily containing an addi-
tional anchor domain which links the enzyme to the
plasma membrane. MT-MMPs actively participate in
the basement membrane degradation either directly or
by activating latent pro-MMP-2 and pro-MMP-13 [3–5].
The plasminogen activation system, composed of two
different plasminogen activators, urokinase-type plas-
minogen activator (uPA) and tissue-type plasminogen
activator (t-PA), both controlled by plasminogen activa-
tor inhibitors (PAI-1 and PAI-2), is also actively involved
in basement membrane degradation either by direct
breakdown of ECM macromolecules or by activating
pro-MMPs [6, 7].
Basement membranes are essentially composed of
type IV collagen, laminins, entactin/nidogen, and hep-
aran sulfate proteoglycans. Type IV collagen is orga-
nized as a network of heterotrimers composed of three
a(IV) chains among six possible, a1(IV) to a6(IV), each
encoded by a specific gene [8]. Each chain comprises
a 7S domain at its N terminus, a large central triple-heli-
cal domain of about 1400 amino acids, and a C-terminal
noncollagenous (NC1) domain of about 240 amino acids.
It is now recognized that NC1 domains from type IV
collagen, but also from other collagen types, display
several biological activities, mainly regulating tumor
invasion and angiogenesis in various cancer types [9].
NC1 a3(IV) chain, also called tumstatin, was first
shown by Maeshima et al. to display antiangiogenic
properties [10].
In previous studies, we demonstrated that the
NC1[a3(IV)185–203] peptide exhibits both in vitro and
in vivo antitumor properties [11, 12]. A shorter CNYYSNS
peptide, corresponding to residues 185–191, shared the
same antitumor properties. The peptide adopts a b-turn
conformation crucial for its biological activity. The aim of
the present study was to design a peptide that contains
both the four residues forming the YSNS b turn and a gly-
cine residue allowing cyclization to constrain the b-turn
conformation, to increase peptide stability and therefore
to increase its biological activity. By nuclear magnetic
resonance (NMR) and molecular modeling, we demon-
strated that the YSNSG cyclopeptide actually adopts
the expected b-turn conformation and exhibits antitu-
mor properties.
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Structure of the YSNSG Linear Peptide
As a starting point of our study, a molecular dynamics
simulation (MDS) was performed at 300K on the linear
YSNSG peptide, either without or with an explicit repre-
sentation of the solvent and starting from a fully ex-
tended conformation. The first MDS in implicit solvent
lasted 50 ns. The main result obtained was the observa-
tion of stable b turns of type I (canonical or close) on
YSNS and/or SNSG (50% of the conformations).
The second MDS in explicit solvent lasted 20 ns. As
a final result, ten clusters (representative structures)
were deduced from the trajectory (data not shown).
Among these clusters, the presence of a YSNS b turn,
an SNSG b turn, intermediate structures, and structures
of extended or quasi-extended conformations could be
noted. According to their 4/c, the YSNS and the SNSG
b turns were found to be very close to two compatible
type I b turns, in perfect agreement with standard
prediction [13].
Structure of the YSNSG Cyclopeptide
First, an MDS of the YSNSG cyclopeptide was
performed under the same conditions as the ones
computed for the linear YSNSG peptide. The main result
obtained was the observation, for the five residues, of
dihedral angles characteristic of type I b turns (canonical
or close) along all the 50 ns of the trajectory, indicating
a stable conformation with a rather rigid backbone.
Second, the YSNSG cyclopeptide structure was ana-
lyzed by NMR. After assignment of all the proton signals
on the TOCSY spectrum, some of the most interesting
information came from the NOESY spectrum, which
clearly indicated correlation between the backbone am-
ide protons of sequential residues whereas no correla-
tion was observed for nonsequential ones. A few other
nuclear Overhauser effects (nOes) were also revealed
by the spectra, in the NH-Ha region (data not shown).
A random conformational search of the peptide struc-
ture was performed under NMR distance constraints
(see Experimental Procedures). Interestingly, the three
independent runs converged to the same conformation
of lowest energy, with an rmsd on all atoms less than 0.2
A˚. This structure (Figure 1) shared a b turn on the YSNS
residues, with a Ca(Y1)-Ca(S4) distance less than 7.0 A˚.
This structure in implicit solvent was stabilized both
by an H bond between the amide proton of tyrosine Y1
and the C=O of serine S4, forming a g turn on the
S4GY1 residues, and by an H bond between the hydroxyl
group of Y1 and the side chain amide function of aspar-
agine N3.
This conformation was further used as a starting point
for an unconstrained MDS that was performed under the
same conditions as those computed for the linear
YSNSG peptide (explicit water, 300K). As expected,
the cyclopeptide was observed as highly constrained,
as indicated by a rmsd value less than 0.5 A˚ on its back-
bone atoms throughout the trajectory (data not shown).
The g turn described above quickly disappeared (during
the heating phase) to reach another stable conforma-
tion. Flexibility of the peptide was further reduced to
the exploration of the different rotamers of the tyrosine
(Figure 2A). The corresponding conformation was char-acterized by a YSNS b turn along the entire trajectory
(Figure 2B). Plotting the 4 and c angles of the peptides
versus time also showed that the five residues were of-
ten located in the a-helical region of the Ramachandran
map, making the YSNS tetrapeptide close to a type I
b turn (Figure 2C). However, senso stricto, this turn did
not belong to any of the canonical types of b turn with
mean 4/c of (290; 266) for both serine S2 and aspar-
agine N3 residues.
This conformation was very close to a b turn spanning
the YSNS sequence described for the linear YSNSG
peptide with a mean rmsd ofw1.5 A˚ calculated on back-
bone atoms.
Comparison between Theoretical and Experimental
Data of the YSNSG Cyclopeptide
To compare our theoretical and experimental results
thoroughly, some proton-proton average distances ex-
tracted from the MDS were plotted (Figure 3). All the
nOes observed experimentally, especially between the
amide protons of sequential residues, corresponded to
mean distances less than 4.0 A˚; on the contrary, the am-
ide protons of the backbone that did not correlate also
corresponded to distances greater than 4.0 A˚. More-
over, we observed that mean values of4 dihedral angles
of the two serine residues were about 290, in agree-
ment with the NMR experiment (2120 6 30).
One particular aspect of the conformation of the pep-
tide observed along the molecular dynamics trajectory
is that all the NHs of its backbone were grouped on
the same side, whereas all the carbonyl groups were
grouped on the other side (Figure S1 in the Supplemen-
tal Data available with this article online). This specific
Figure 1. Minimal Energy Conformation of the YSNSG Cyclopep-
tide
This conformation shares the lowest potential energy and comes
from the random conformational search of the YSNSG cyclopep-
tide in implicit solvent (using a distance-dependent dielectric
constant). This structure is built in agreement with our NMR data
(experimentally observed nOes that were included as constraints
during the minimization process are reported as dashed lines).
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1309Figure 2. The Stable Structure of the YSNSG Cyclopeptide as Observed along the 20 ns Molecular Dynamics Trajectory
The simulation is performed in an explicit water box and shows a stable YSNS b turn.
(A) Flexibility of the peptide is reduced to the tyrosine side chain.
(B) The stable structure of the peptide, characterized by a YSNS b turn along the entire trajectory, presents the particularity to separate NH and
C=O of its backbone on each of its sides, also preventing internal H bonds.
(C) Plotting the 4 and c angles of the peptides shows that the five residues are often located in the a-helical region of the Ramachandran map,
with mean 4/c of (290; 266) for both serine S2 and asparagine N3 residues, making the YSNS tetrapeptide close to a type I b turn.feature prevents the formation of backbone internal hy-
drogen bonds, in agreement with the NMR experimental
data. The temperature coefficients of the amide protons
of the peptide, which were recorded between 295K and
320K, failed to reveal any internal H bond, with values of
210.0, 24.6, 27.0, 24.6, and 26.1 ppb/K for Y1, S2, N3,S4, and G5, respectively (usually values < 24.5 ppb/K
correspond to the absence of an H bond) (Figure S1).
Thus, the peptide appears to be highly polarized, as
shown by the electrostatic potential of the cyclopeptide
(isovalues of +7.5 and27.5 kT/e in blue and red, respec-
tively). The charge distribution was computed by usingFigure 3. Comparison of Experimental and
Theoretical Proton-Proton Distances of the
YSNSG Cyclopeptide
The nOes experimentally obtained are
reported in white and the theoretical in
black. The mean proton-proton distances
are extracted from trajectories of the molec-
ular dynamic simulations performed on the
YSNSG cyclopeptide.
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method [14] as implemented in VMD [15]. Interestingly,
the positive charges encompassed the side chains of
the SNS residues that are known to be crucial for biolog-
ical activity of the native peptide or its derivatives, a
feature that may also be important for its binding to
aVb3 integrin [16].
Secondary Structure Characterization by Electronic
Circular Dichroism Spectroscopy
The circular dichroism (CD) spectra of the YSNSG cyclo-
peptide recorded at pH 7 and at various temperatures
did not clearly demonstrate the presence of an ordered
conformation. The same results were observed without
adding any buffer, also keeping a pH of 3; this showed
a poor sensitivity of the peptide to temperature and
pH, probably due to its highly constrained conformation
(data not shown). The observed CD shape is therefore
not characteristic of any of the classical b-turn confor-
mations (type I, type II, or type VIII); this is probably
due to the distorted 4/c of the peptide as compared to
a type I b turn.
NMR and molecular modeling results showed that the
YSNSG cyclopeptide actually adopted the expected
b-turn conformation on the YSNS residues. This confor-
mation did not depend on temperature and pH, suggest-
ing a higher stability than that of the native peptide. It
also showed the particularity that all its peptide bonds
are in trans conformation without any internal H bond;
indeed, all its amine and carboxyl backbone groups
were grouped on opposite sides of the peptide. This
distribution pattern of electrostatic potential is an impor-
tant feature that should be taken into consideration for
the binding of the cyclopeptide to aVb3 integrin.
In the second part of the study, we compared YSNSG
cyclopeptide biological activity to that of the native
CNYYSNS peptide.
Effect of the YSNSG Cyclopeptide on UACC-903
Human Melanoma Cell Adhesion, Proliferation,
and Migration
The native CNYYSNS peptide (NP7) and the YSNSG
cyclopeptide (C5) promoted UACC-903 melanoma cell
adhesion like the NC1[a3(IV)185–203] peptide (Fig-
ure 4A). Cell adhesion was inhibited by a preincubation
of melanoma cells with an anti-aVb3 integrin antibody,
whereas an anti-b1 antibody had no effect (data not
shown). This result confirms that, like NP7 [16], C5 inter-
acts with aVb3 integrin. Competition assays demon-
strated that, like the NC1[a3(IV)185–203] peptide [16],
NP7 and C5 also inhibited the adhesion of UACC-903
cells to NC1[a3(IV)185–203]-coated culture plates. The
treatment of melanoma cells with the NC1[a3(IV)185–
203] also prevented their adhesion to both NP7 and
C5. This result suggests that C5 binds to aVb3 integrin
at the same site as the NP7 and NC1[a3(IV)185–203]
peptides.
Tumor progression depends on cell proliferation and
migration. The in vitro proliferation of UACC-903 human
melanoma cells was significantly inhibited by the
CNYYSNS peptide (245%). The YSNSG cyclopeptide
at 5, 10, and 20 mM also inhibited UACC-903 melanoma
cell proliferation by 27%, 29%, and 40%, respectively
(Figure 4B). The cyclopeptide was as efficient as thenative peptide at the same concentration. The effect of
the YSNSG cyclopeptide on UACC-903 cell migration
through an in vitro-reconstituted basement membrane
Figure 4. Effect of the YSNSG Cyclopeptide on UACC-903 Mela-
noma Cell Adhesion, Proliferation, and Migration
(A) UACC-903 melanoma cell adhesion is measured after nuclei
staining with crystal violet. Cells are seeded onto plastic, native
NC1[a3(IV)185–203] peptide-, native CNYYSNS peptide NP7-, or
YSNSG cyclopeptide C5-coated plates with or without preincuba-
tion with competitors.
(B) UACC-903 cell proliferation is determined using WST-1 reagent.
Cells are incubated in 24-well culture plates for 48 hr with either
control medium (C), YSNSG cyclopeptide (C5), or CNYYSNS native
peptide (NP7).
(C) UACC-903 cell invasion is assayed in modified Boyden cham-
bers. After a 72 hr incubation period, migrated cells are stained
with crystal violet and counted with an inverted microscope.
C, control; C5, YSNSG cyclopeptide (20 mM); NP7, CNYYSNS native
peptide (20 mM).
*, significantly different from control at p < 0.05. **, significantly
different from control at p < 0.01.
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10% fetal calf serum as a chemoattractant. Migration
was assessed after 72 hr. The YSNSG cyclopeptide
(20 mM) induced a 47% decrease of UACC-903 cell mi-
gration, similar to the CNYYSNS peptide at the same
concentration (Figure 4C).
Effect of the YSNSG Cyclopeptide on Matrix
Metalloproteinases and Their Inhibitors
The matrix metalloproteinase activation cascade is
largely involved in ECM degradation.
No significant changes in MMP-2 and MMP-9 secre-
tion were detected by gelatin zymography on cell media
after incubation of the UACC-903 cells with either the
YSNSG cyclopeptide or the native CNYYSNS peptide
(data not shown).
Secretion of TIMPs into the conditioned culture
medium was analyzed by reverse zymography. A dose-
dependent increase in TIMP-2 secretion was observed
in the cultures incubated with YSNSG cyclopeptide, as
well as with CNYYSNS (Figure 5A). An ELISA measure-
ment of TIMP-2 secretion also confirmed this result
(data not shown). TIMP-1 and TIMP-3 secretion were
not altered.
The YSNSG cyclopeptide strongly inhibited pro-
MMP-14 expression, as demonstrated by western blot
analysis (Figure 5B). Pro-MMP-14 activation was also
completely abolished. The inhibitory effects of the cy-
clopeptide were of the same intensity as the native pep-
tide. The treatment of UACC-903 cells with either the
YSNSG cyclopeptide or the native CNYYSNS peptide
also largely decreased the binding of pro-MMP-2 to tu-
mor cell membrane and its activation (Figure 5C).
MMP-14 is able to degrade ECM (types I–III collagens,
fibronectin, laminins, fibrin, gelatin, nidogen, and carti-
lage proteoglycan core proteins). It is inhibited by
TIMP-2 [17]. In our model, TIMP-2 secretion was signif-
icantly increased by incubation with either the YSNSG
cyclopeptide or the native CNYYSNS peptide. The ex-
pression and activation of MMP-14 were also strongly
inhibited, leading to a large decrease in the activation
of pro-MMP-2 associated with tumor cell membrane.
This should explain, at least partially, the strong reduc-
tion in the invasive capacities of melanoma cells.
Effect of the YSNSG Cyclopeptide
on the Plasminogen Activation System
Another proteolytic cascade involved in tumor invasion
is the activation of plasminogen into plasmin by plas-
minogen activators u-PA and t-PA [6]. Secretion of
u-PA and t-PA was analyzed by gelatin-plasminogen
zymography (Figure 6A). Treatment of UACC-903 cells
with the YSNSG cyclopeptide induced a dose-depen-
dent decrease in both u-PA and t-PA secretion, up to
256% and 255%, respectively, more efficiently than
the native CNYYSNS peptide (240% and 248%, re-
spectively). Secretion of PAI-1, the u-PA and t-PA inhib-
itor, was analyzed by western blot (Figure 6B). Treat-
ment of UACC-903 cells with the YSNSG cyclopeptide
(20 mM) induced a 4.0-fold increase in PAI-1 secretion
versus a 3.4-fold increase with the native CNYYSNS
peptide at the same concentration.
Collectively, the inhibition of MMP-2/MMP-14 and
plasminogen activation may explain most of the de-crease in ECM degradation and the inhibition of in vitro
tumor cell migration.
Inhibition of In Vivo Tumor Growth
by the YSNSG Cyclopeptide
In previous studies [12], we demonstrated that the peri-
tumor injection of the native CNYYSNS peptide inhibited
tumor growth. In the current paper, we used other ex-
perimental conditions. Melanoma cells were subcutane-
ously injected into the left side of syngenic C57BL6
mice. Tumors appeared at day 6. Intraperitoneal injec-
tions of either native CNYYSNS peptide or YSNSG
cyclopeptide were performed at day 6, 8, and 11 (10
mg/kg). Tumors were measured at day 14 (Figure 7).
The YSNSG cyclopeptide inhibited tumor cells by 46%
and the native CNYYSNS peptide by 27%, strongly sug-
gesting that the cyclopeptide is more stable than the
native peptide after systemic administration.
The design of cyclic RGD-containing peptides to
antagonize aVb3 integrin clearly demonstrated that cy-
clization confers to these peptides a large increase in
Figure 5. Effect of the YSNSG Cyclopeptide on the Pro-MMP-2
Activation Cascade
UACC-903 melanoma cells are incubated for 48 hr with control me-
dium (C), YSNSG cyclopeptide (C5), or CNYYSNS native peptide
(NP7).
(A) TIMP secretion is analyzed by reverse zymography on condi-
tioned media.
(B) MMP-14 expression and activation in cell extracts are analyzed
by western blot (pro-MMP-14, empty bars; MMP-14, hatched bars).
(C) Pro-MMP-2 activation in cell extracts is analyzed by gelatin
zymography (pro-MMP-2, empty bars; MMP-2, hatched bars).
Quantifications are performed by densitometry using Bio-1D soft-
ware (Vilber Lourmat, Marne-la-Valle´e, France). Results are ex-
pressed as arbitrary units (A.U.).
*, significantly different from control at p < 0.05. **, significantly dif-
ferent from control at p < 0.01.
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proved bioavailability as reported in the literature [18–
20]. This is in agreement with our results suggesting
a higher stability of the YSNSG cyclopeptide versus
the native CNYYSNS peptide. Our experimental data
also confirmed that the binding of tumstatin-derived
peptides to aVb3 integrin requires a b turn located on
the YSNS residues. The tumstatin-derived peptides act
as aVb3 integrin antagonists.
The cyclic conformation of the YSNSG peptide and its
stability at low pH should suggest this peptide as a po-
tent antitumor therapeutic agent which might be admin-
istered per os or intraperitoneally.
Significance
Increasing interest is presently devoted to specific do-
mains of extracellular matrix macromolecules which
are able to regulate cell activities (matrikines). Type
IV basement membrane collagen was recently demon-
strated to be a source of various matrikines which may
play an important role in limiting cancer progression.
The C-terminal noncollagenous NC1 domains from
type IV collagen inhibit tumor invasion and/or angio-
genesis in various cancer types. We previously dem-
Figure 6. Inhibition of Plasminogen Activator Secretion by the
YSNSG Cyclopeptide
UACC-903 melanoma cells are incubated for 48 hr with control
medium (C), YSNSG cyclopeptide (C5), or CNYYSNS native peptide
(NP7).
(A) u-PA and t-PA secretion into the conditioned media are ana-
lyzed by gelatin-plasminogen zymography.
(B) PAI-1 secretion into the conditioned media is analyzed by west-
ern blot.
Quantifications are performed by densitometry using Bio-1D soft-
ware. Results are expressed as arbitrary units (A.U.).
**, significantly different from control at p < 0.01.onstrated that the CNYYSNS sequence from the NC1
domain of type IV collagen a3 chain inhibited tumor
progression in an in vivo mouse melanoma model,
through binding to aVb3 integrin. The YSNS residues
formed a b turn crucial for biological activity. The
aim of the present study was to design a YSNSG cyclo-
peptide with a constrained b turn on the YSNS resi-
dues, more active and stable than native CNYYSNS.
By nuclear magnetic resonance and molecular model-
ing, we demonstrated that the YSNSG cyclopeptide
actually adopted the expected b-turn conformation
and inhibited melanoma cell proliferation and invasive
properties as well as the native CNYYSNS pep-
tide. Moreover, intraperitoneal administration of the
YSNSG cyclopeptide after tumor development in-
hibited melanoma progression far more efficiently
than the native peptide. The increased solubility and
stability at low pH of the YSNSG cyclopeptide suggest
that this peptide might be used as a potent antitumor
therapeutic agent.
Experimental Procedures
Reagents
Culture reagents and molecular biology products were from Invitro-
gen (Cergy Pontoise, France). Bovine serum albumin, gelatin, and
Matrigel (ECM gel) were purchased from Sigma (St-Quentin
Fallavier, France). Human plasminogen was from Calbiochem
(VWR International, Strasbourg, France). Anti-human MMP-14 and
anti-human aVb3 integrin antibodies (Chemicon, Euromedex, Souf-
felweyersheim, France) and anti-human PAI-1 antibody (American
Diagnostica, Neuville sur Oise, France) were also used. The Biotrak
ELISA evaluation kit of TIMP-2 and the enhanced chemilumines-
cence kit were from Amersham (Saclay, France).
Peptides
The native NC1[a3(IV)185–191] CNYYSNS peptide was obtained by
solid-phase synthesis using an FMOC derivative procedure and
was further purified by reverse phase HPLC with a C18 column by
elution with a gradient of acetonitrile in trifluoroacetic acid, and
Figure 7. Inhibition of In Vivo Tumor Growth by the YSNSG Cyclo-
peptide
B16F1 cells are subcutaneously injected into syngenic C57BL6
mice (2.5 3 105 cells per mouse). Intraperitoneal administrations
of either YSNSG cyclopeptide (C5) or CNYYSNS native peptide
(NP7) (10 mg/kg) are performed at day 6, 8, and 11. Tumor volume
is measured at day 14. Statistical significance is determined using
the nonparametric u-test of Mann and Whitney.
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chased from Ansynth Service B.V. (Roosendaal, The Netherlands).
The native NC1[a3(IV)185–203] peptide was from Covalab (Oullins,
France). For the determination of biological activities, the peptides
were extemporaneously dissolved in dimethyl sulfoxide (DMSO);
the final DMSO concentration was lower than 0.2% (v/v) in all exper-
iments.
NMR
All NMR spectra were recorded on a Bruker DRX 500 spectrometer
(Bruker, Wissembourg, France). The sample was dissolved in a 9:1
D2O:H2O mixture. TSP-d4 was used as an internal chemical shift
standard. Water proton signals were suppressed by the WATER-
GATE sequence. The chemical shift dependence of amide protons
was studied at 294K, 300K, 305K, 310K, 315K, and 320K. The iden-
tification of the spin systems was achieved by analysis of the TOCSY
spectrum (200 ms mixing time, mlevdpst19 pulse sequence). The
classification of interproton distances was drawn from the NOESY
spectrum (350 ms mixing time, noesygpst19 pulse sequence). The
acquisition matrix of the latter contained 5123 2048 data points, ex-
tended to 10243 4096 by zero filling. A cosine-squared apodization
function was applied in both dimensions prior to 2D Fourier transfor-
mation.
Circular Dichroism
CD spectra of the YSNSG cyclopeptide were recorded on a JASCO
J-810 CD spectropolarimeter (JASCO France, Bouguenais, France)
equipped with a PTC-623S Peltier temperature control system by
using a cell of 0.2 mm optical path length. The peptide was dissolved
at a concentration of 400 mM either in water (pH 3) or in a 20 mM po-
tassium phosphate buffer to bring the solution to pH 7. Three scans
were accumulated in the spectral range of 190–250 nm at a temper-
ature of 0C, 20C, 37C, and 50C by taking points every 0.1 nm.
Random Conformational Search of the YSNSG Cyclopeptide
We performed a random conformational search of the structure of
the YSNSG cyclopeptide under NMR data constraints, in implicit
water solvent, with a distance-dependent dielectric constant, by
using the CHARMM program and force fields (PARAM set 22) [21,
22]. The geometrical distances corresponding to our experimentally
observed nOes were constrained to be in the range of 2.0–4.0 A˚.
Additionally, distances between amide protons of the backbone
that did not correlate were constrained to be in the range of 4.0–
8.0 A˚. Because we did not observe any Ha-Ha correlations in the
NOESY spectrum (data not shown), all the peptide bonds were
also constrained to be in trans conformation (u w 180); finally,
and in agreement with the Karplus relation modified by Pardi et al.
[23], the 4 angles of the two serine residues (S2 and S4) were also
constrained around 2120 6 30 according to 3J(NH-Ha) constant
coupling values of 8.2 and 8.8 Hz, respectively (other residues
shared values between 5.0 and 7.0 Hz).
At each step of our random conformational search protocol, we
randomized all the backbone dihedral angles of the peptide and
minimized the corresponding structure according to the NMR con-
straints described above. Each generated model was minimized
using both Steepest Descent and Adopted Based Newton Raphson
algorithms until an energy gradient of 1025 kcal/mol was reached.
Three fully independent runs of 1000 steps were performed by
changing the initial seed of the random number generator. Finally,
the 3000 generated minimized structures were grouped for analysis.
Molecular Dynamics Simulations
First, both the YSNSG linear and cyclopeptides were studied
through MDS in water implicit solvent. The surface-accessible
solvent area (SASA) model was used as a solvation model [24].
The solvent effect on the peptide included the EEF1 (energy effective
function) model proposed by Lazaridis and Karplus [25]. Then, the
peptides were studied in explicit solvent.
For the linear peptide, the starting point of the two MDSs was
a fully extended conformation; for the cyclopeptide, the MDS started
from the minimum energy conformations that were obtained either
just after cyclization of the linear peptide or by the random confor-
mational search described above. For MDS in explicit solvent,
each peptide was first embedded in a water box ensuring 8 A˚ ofwater (TIP3P) on each of their sides. The systems were then energy
minimized by 2000 steps of conjugate gradient and brought to room
temperature (300K) by using the NAMD program [26, 27]. The two
simulations were performed in the number of particles, pressure,
and temperature (NPT) ensemble (1 atm; 300K) using the Verlet algo-
rithm and an integration step of 10215 s. Electrostatic interactions
were treated by applying a switch function to the classical potential
between 10 A˚ and 12 A˚ (cutoff value). A conformational analysis was
performed on the full-length simulations that reached 20 ns, extract-
ing the structures of the peptides each 10 ps of the trajectories.
These models were grouped into a reduced number of clusters
using NMRCLUST software [28] and a threshold of 2.5 A˚ for the
clustering cutoff.
Animals
Female C57BL6 mice (average body weight, 18–20 g) were pur-
chased from Harlan France (Gannat, France). Animals were individ-
ually caged and given food and water ad libitum. They were kept in
a room with constant temperature and humidity. All mice were accli-
matized to our laboratory conditions for 1 week before starting the
experiments. The in vivo experiments were conducted according
to the recommendations of the Centre National de la Recherche
Scientifique.
Cell Cultures
B16F1 cells, a lung metastatic subline of murine B16 melanoma,
were a generous gift from Dr. M. Gre´goire (INSERM U419, Nantes,
France). UACC-903 cells, a melanoma cell line, were from Dr. J. Trent
(Georgetown University Medical Center, Washington, DC). B16F1
cells were cultured in RPMI 1640 and UACC-903 in Dulbecco’s
modified Eagle’s medium (DMEM) containing glucose 4.5 g/l, both
supplemented with 5% fetal bovine serum (FBS) in 25 cm2 flasks
(Nunclon, Dutscher, Brumath, France) under a humidified atmo-
sphere of 5% CO2 in air.
Cell Adhesion and Proliferation Measurements
Cell adhesion was measured on peptide-coated 96-well plates
(Immunosorb, Nunclon, Dutscher, Brumath, France). Peptides
were dissolved in DMSO and diluted in carbonate buffer (pH 10.0)
and deposited onto 96-well plates at 4C under sterile conditions.
Cell adhesion was evaluated by absorbance at 560 nm after nuclei
staining with crystal violet. For competition assays, cells were prein-
cubated for 15 min with the competing peptides and then deposited
onto peptide-coated 96-well plates as described above.
Cell proliferation was determined using WST-1 reagent according
to the manufacturer’s instructions (Roche Diagnostics, Meylan,
France). In all experiments, cell viability was greater than 98%, as
assessed by trypan blue exclusion.
In Vitro Invasion Assays
Invasion was assayed in modified Boyden chambers (ThinCert,
tissue culture insert for 24-well plates, 8.36 mm inner diameter,
8 mm pore, Greiner Bio-one, Courtaboeuf, France) as previously
described [11].
Zymography Analyses
Cell Incubation with the Peptides
At subconfluence, cells were washed twice with phosphate-
buffered saline to remove residual FBS and incubated for 48 hr in
DMEM, with or without the peptides, at concentrations ranging
from 0 to 20 mM. Conditioned media were harvested and centrifuged
at 500 3 g for 10 min at 4C to remove cellular debris. Protein con-
tents of the media were determined by the Bradford method, using
bovine serum albumin as a standard [29].
Gelatin Zymography
The expression and activation of pro-MMP-2 and pro-MMP-9 in
conditioned media or in cell membrane extracts of UACC-903 cells,
treated or not with the peptides, were analyzed by gelatin zymogra-
phy as previously described [11].
The secretion of TIMP-2 was analyzed on UACC-903-conditioned
media by reverse gelatin zymography as previously described [11].
TIMP-2 secretion was also measured using a Biotrak ELISA kit,
according to the manufacturer’s instructions.
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For the determination of plasminogen activators, UACC-903-
conditioned media were analyzed on SDS-polyacrylamide gels
containing 1 mg/ml gelatin and 10 mg/ml plasminogen as previously
described [30].
Western Blot Analysis
Samples were electrophoresed in a 0.1% SDS, 10% polyacrylamide
gel. They were then transferred onto Immobilon-P membranes (Milli-
pore, St Quentin en Yvelines, France). The membranes were blocked
with 5% nonfat dry milk, 0.1% Tween 20 in a 50 mM Tris-HCl buffer,
150 mM NaCl (pH 7.5) (TBS) for 2 hr at room temperature and incu-
bated overnight at 4C with anti-MMP-14 or anti-PAI-1 antibody and
then for 1 hr at room temperature with a second peroxidase-conju-
gated anti-IgG antibody. Immune complexes were visualized with
the enhanced chemiluminescence detection kit.
In Vivo Tumor Growth Measurement
Suspensions of B16F1 cells (2.5 3 105 cells in 0.1 ml RPMI 1640
medium) were subcutaneously injected into the left side of different
series of syngenic C57BL6 mice. Tumors appeared at day 6 and in-
traperitoneal administrations of peptides were performed at day 6,
8, and 11. Tumor sizes were measured every 2 days. Tumor volume
was determined according to v = 0.5 A 3 B2, where A denotes
the largest dimension of the tumor and B represents the smallest
dimension [31].
Statistical Analyses
All in vitro experiments were done in quadruplicate. Statistical anal-
yses were performed by Student’s t test. Results were expressed as
mean 6 1 standard deviation. For in vivo experiments, volumes of
primary tumors were statistically analyzed using the nonparametric
u-test of Mann and Whitney and the parametric Student’s t test
paired with weight-matched mice.
Supplemental Data
Supplemental Data include one figure and can be found with this
article online at http://www.chembiol.com/cgi/content/full/13/12/
1307/DC1/.
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